💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Methantheline

CHEMBL1201264 Phase 4 Approuvé Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
340.4 g/mol
LogP
3.3
Phase
4

This anticholinergic drug blocks muscarinic receptors in the gut and bladder, reducing smooth muscle spasms and secretions, making it useful for treating peptic ulcers, irritable bowel syndrome, and excessive sweating. It has been largely replaced by more selective and better-tolerated medications.

Masse moléculaire

340,4000 g/mol

LogP

3,30

TPSA

35,50 Ų

Règle des 5 de Lipinski

Conforme

Mécanisme d'action

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21

                

                

                
                

                    
InChI

                    
InChI=1S/C21H26NO3/c1-4-22(3,5-2)14-15-24-21(23)20-16-10-6-8-12-18(16)25-19-13-9-7-11-17(19)20/h6-13,20H,4-5,14-15H2,1-3H3/q+1

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H26NO3+

                    

                    
                    

                        
HBD / HBA

                        
- / 3

                    

                    
                    

                        
Liaisons Rotatives

                        
7

                    

                    
                    
                    

                        
Atomes Lourds

                        
25

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
This anticholinergic drug blocks muscarinic receptors in the gut and bladder, reducing smooth muscle spasms and secretions, making it useful for treating peptic ulcers, irritable bowel syndrome, and excessive sweating. It has been largely replaced by more selective and better-tolerated medications.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Methantheline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201264.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4097.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.